a - inclusion criteria (except fluoxetine + budesonide and paracetamol arms): 1. patients over 18 years old with the ability to provide free and informed consent 2. acute flu-like symptoms \< 07 days. 3. patients with at least one enhancement criteria: 1. the. age \> 50 years old (does not need any of the other criteria) 2. diabetes mellitus requiring oral medication or insulin 3. systemic arterial hypertension requiring at least 01 oral medication for treatment 4. known cardiovascular diseases (heart failure, congenital heart disease, valvular disease, coronary artery disease, cardiomyopathies under treatment, clinically manifest heart diseases with clinical repercussions) 5. symptomatic and/or treated lung disease (emphysema, fibrosing diseases) 6. patients with symptomatic asthma requiring chronic use of agents to control symptoms. 7. obesity, defined as bmi \> 30 kg/m2 in weight and height information provided by the patient; 8. transplant patients 9. patient with stage iv chronic kidney disease or on dialysis. 10. patient with temperature measured at screening \> 38º c. 11. patients with at least one of the following symptoms: cough, dyspnea, ventilator-dependent chest pain or myalgias with limitation of daily activities (criterion limited to 25% of randomizations) 12. immunosuppressed patients/using corticosteroid therapy (equivalent to a maximum of 10 mg of prednisone per day) and/or immunosuppressive therapy) 13. patients with a history of cancer in the last 5 years or currently undergoing oncological treatment 4. patient with positive rapid test for sars-cov2 antigen performed on occasion of the screening or patient with a positive sars-cov2 diagnostic test within 07 days of the onset of symptoms. 5. willingness to use the proposed investigative treatment and follow the protocol-related procedures foreseen in the research. 6. signing the free and informed consent form before any research procedures b - inclusion criteria for the fluoxetine + budesonide combination arm (07 days of treatment - partnership with the "anticov consortium"): 1. patients over 18 years of age with the ability to provide free and informed consent. 2. patients treated at a basic health unit of the unified health system (sus) or patients treated at emergency care units of the sus or supplementary medicine with an acute clinical condition compatible with covid 19. 3. patients over 18 years of age and a history of at least one of the following criteria. 1. diabetes mellitus, heart disease, chronic kidney disease, chronic obstructive pulmonary disease, cerebrovascular diseases or patients considered to be underweight or overweight according to the investigator's judgment (bmi ≤ 16 or bmi \> 25). or 2. individuals aged ≥ 60 years without co-morbidities. 4) covid-19 confirmed by molecular or antigenic test for sars-cov-2 within up to 24 hours prior to screening and a maximum of 2 days after sample collection. 5) viral syndrome with or without pneumonia and arterial o2 saturation \> 94%. 6) signing the free and informed consent form before any research procedures. 7) willingness to use the proposed investigational treatment and follow the procedures provided for in the research.

a - inclusion criteria (except fluoxetine + budesonide and paracetamol arms): 1. patients over 18 years old with the ability to provide free and informed consent 2. acute flu-like symptoms \< 07 days. 3. patients with at least one enhancement criteria: 1. the. age \> 50 years old (does not need any of the other criteria) 2. diabetes mellitus requiring oral medication or insulin 3. systemic arterial hypertension requiring at least 01 oral medication for treatment 4. known cardiovascular diseases (heart failure, congenital heart disease, valvular disease, coronary artery disease, cardiomyopathies under treatment, clinically manifest heart diseases with clinical repercussions) 5. symptomatic and/or treated lung disease (emphysema, fibrosing diseases) 6. patients with symptomatic asthma requiring chronic use of agents to control symptoms. 7. obesity, defined as bmi \> 30 kg/m2 in weight and height information provided by the patient; 8. transplant patients 9. patient with stage iv chronic kidney disease or on dialysis. 10. patient with temperature measured at screening \> 38º c. 11. patients with at least one of the following symptoms: cough, dyspnea, ventilator-dependent chest pain or myalgias with limitation of daily activities (criterion limited to 25% of randomizations) 12. immunosuppressed patients/using corticosteroid therapy (equivalent to a maximum of 10 mg of prednisone per day) and/or immunosuppressive therapy) 13. patients with a history of cancer in the last 5 years or currently undergoing oncological treatment 4. patient with positive rapid test for sars-cov2 antigen performed on occasion of the screening or patient with a positive sars-cov2 diagnostic test within 07 days of the onset of symptoms. 5. willingness to use the proposed investigative treatment and follow the protocol-related procedures foreseen in the research. 6. signing the free and informed consent form before any research procedures b - inclusion criteria for the fluoxetine + budesonide combination arm (07 days of treatment - partnership with the "anticov consortium"): 1. patients over 18 years of age with the ability to provide free and informed consent. 2. patients treated at a basic health unit of the unified health system (sus) or patients treated at emergency care units of the sus or supplementary medicine with an acute clinical condition compatible with covid 19. 3. patients over 18 years of age and a history of at least one of the following criteria. 1. diabetes mellitus, heart disease, chronic kidney disease, chronic obstructive pulmonary disease, cerebrovascular diseases or patients considered to be underweight or overweight according to the investigator's judgment (bmi ≤ 16 or bmi \> 25). or 2. individuals aged ≥ 60 years without co-morbidities. 4) covid-19 confirmed by molecular or antigenic test for sars-cov-2 within up to 24 hours prior to screening and a maximum of 2 days after sample collection. 5) viral syndrome with or without pneumonia and arterial o2 saturation \> 94%. 6) signing the free and informed consent form before any research procedures. 7) willingness to use the proposed investigational treatment and follow the procedures provided for in the research.

a - inclusion criteria (except fluoxetine + budesonide and paracetamol arms): patients over 18 years old with the ability to provide free and informed consent acute flu-like symptoms < 07 days. patients with at least one enhancement criteria: the. age > 50 years old (does not need any of the other criteria) diabetes mellitus requiring oral medication or insulin systemic arterial hypertension requiring at least 01 oral medication for treatment known cardiovascular diseases (heart failure, congenital heart disease, valvular disease, coronary artery disease, cardiomyopathies under treatment, clinically manifest heart diseases with clinical repercussions) symptomatic and/or treated lung disease (emphysema, fibrosing diseases) patients with symptomatic asthma requiring chronic use of agents to control symptoms. obesity, defined as bmi > 30 kg/m2 in weight and height information provided by the patient; transplant patients patient with stage iv chronic kidney disease or on dialysis. patient with temperature measured at screening > 38º c. patients with at least one of the following symptoms: cough, dyspnea, ventilator-dependent chest pain or myalgias with limitation of daily activities (criterion limited to 25% of randomizations) immunosuppressed patients/using corticosteroid therapy (equivalent to a maximum of 10 mg of prednisone per day) and/or immunosuppressive therapy) patients with a history of cancer in the last 5 years or currently undergoing oncological treatment patient with positive rapid test for sars-cov2 antigen performed on occasion of the screening or patient with a positive sars-cov2 diagnostic test within 07 days of the onset of symptoms. willingness to use the proposed investigative treatment and follow the protocol-related procedures foreseen in the research. signing the free and informed consent form before any research procedures b - inclusion criteria for the fluoxetine + budesonide combination arm (07 days of treatment - partnership with the "anticov consortium"): patients over 18 years of age with the ability to provide free and informed consent. patients treated at a basic health unit of the unified health system (sus) or patients treated at emergency care units of the sus or supplementary medicine with an acute clinical condition compatible with covid 19. patients over 18 years of age and a history of at least one of the following criteria. diabetes mellitus, heart disease, chronic kidney disease, chronic obstructive pulmonary disease, cerebrovascular diseases or patients considered to be underweight or overweight according to the investigator's judgment (bmi ≤ 16 or bmi > 25). or individuals aged ≥ 60 years without co-morbidities. 4) covid-19 confirmed by molecular or antigenic test for sars-cov-2 within up to 24 hours prior to screening and a maximum of 2 days after sample collection. 5) viral syndrome with or without pneumonia and arterial o2 saturation > 94%. 6) signing the free and informed consent form before any research procedures. 7) willingness to use the proposed investigational treatment and follow the procedures provided for in the research.

a - inclusion criteria (except fluoxetine + budesonide and paracetamol arms): patients over 18 years old with the ability to provide free and informed consent acute flu-like symptoms < 07 days. patients with at least one enhancement criteria: the. age > 50 years old (does not need any of the other criteria) diabetes mellitus requiring oral medication or insulin systemic arterial hypertension requiring at least 01 oral medication for treatment known cardiovascular diseases (heart failure, congenital heart disease, valvular disease, coronary artery disease, cardiomyopathies under treatment, clinically manifest heart diseases with clinical repercussions) symptomatic and/or treated lung disease (emphysema, fibrosing diseases) patients with symptomatic asthma requiring chronic use of agents to control symptoms. obesity, defined as bmi > 30 kg/m2 in weight and height information provided by the patient; transplant patients patient with stage iv chronic kidney disease or on dialysis. patient with temperature measured at screening > 38º c. patients with at least one of the following symptoms: cough, dyspnea, ventilator-dependent chest pain or myalgias with limitation of daily activities (criterion limited to 25% of randomizations) immunosuppressed patients/using corticosteroid therapy (equivalent to a maximum of 10 mg of prednisone per day) and/or immunosuppressive therapy) patients with a history of cancer in the last 5 years or currently undergoing oncological treatment patient with positive rapid test for sars-cov2 antigen performed on occasion of the screening or patient with a positive sars-cov2 diagnostic test within 07 days of the onset of symptoms. willingness to use the proposed investigative treatment and follow the protocol-related procedures foreseen in the research. signing the free and informed consent form before any research procedures b - inclusion criteria for the fluoxetine + budesonide combination arm (07 days of treatment - partnership with the "anticov consortium"): patients over 18 years of age with the ability to provide free and informed consent. patients treated at a basic health unit of the unified health system (sus) or patients treated at emergency care units of the sus or supplementary medicine with an acute clinical condition compatible with covid 19. patients over 18 years of age and a history of at least one of the following criteria. diabetes mellitus, heart disease, chronic kidney disease, chronic obstructive pulmonary disease, cerebrovascular diseases or patients considered to be underweight or overweight according to the investigator's judgment (bmi ≤ 16 or bmi > 25). or individuals aged ≥ 60 years without co-morbidities. 4) covid-19 confirmed by molecular or antigenic test for sars-cov-2 within up to 24 hours prior to screening and a maximum of 2 days after sample collection. 5) viral syndrome with or without pneumonia and arterial o2 saturation > 94%. 6) signing the free and informed consent form before any research procedures. 7) willingness to use the proposed investigational treatment and follow the procedures provided for in the research.

a - inclusion criteria (except fluoxetine + budesonide and paracetamol arms): patients over 18 years old with the ability to provide free and informed consent acute flu-like symptoms < 07 days. patients with at least one enhancement criteria: age > 50 years. diabetes mellitus requiring oral medication or insulin. systemic arterial hypertension requiring at least 01 oral medication for bp control. known cardiovascular diseases (heart failure, congenital heart disease, valvar heart valve disease, coronary artery disease, cardiomyopathies). symptomatic lung disease (emphysema, chronic bronchitis). symptomatic asthma patients requiring chronic use of agents for control of symptoms. fever > 38 c at baseline. obesity, defined as bmi> 30 kg / m2 body weight. transplanted patients. patient with stage iv chronic kidney disease or on dialysis. immunosuppressed patients/ using corticosteroid therapy (equivalent to maximum 10 mg of prednisone per day) and/ or immunosuppressive therapy). patients with a history of cancer in the last 05 years or undergoing treatment of a current cancer. chronic renal disease kdigo iv or end-stage renal disease on chronic ambulatory renal replacement therapy. patients with important limitation of daily activities due to: dyspnea, chest pain myalgia (limited to 25% of all randomizations). patient with positive rapid test for sars-cov2 antigen performed on occasion of the screening or patient with a positive sars-cov2 diagnostic test within 07 days of the onset of symptoms. willingness to use the proposed investigative treatment and follow the protocol-related procedures foreseen in the research. specific inclusion criteria for the fluvoxamine arm: present significant dyspnea, arterial hypotension, severe dehydration or spo2 between 85 to 93% in room air at admission and medical decision to discharge patient home, with an observation period at er not exceeding 12 hours. b - inclusion criteria for the fluoxetine + budesonide combination arm (07 days of treatment - partnership with the "anticov consortium"): patients over 18 years of age with the ability to provide free and informed consent. patients treated at a basic health unit of the unified health system (sus) or patients treated at emergency care units of the sus or supplementary medicine with an acute clinical condition compatible with covid 19. patients over 18 years of age and a history of at least one of the following criteria. diabetes mellitus, heart disease, chronic kidney disease, chronic obstructive pulmonary disease, cerebrovascular diseases or patients considered to be underweight or overweight according to the investigator's judgment (bmi ≤ 16 or bmi > 25). or individuals aged ≥ 60 years without co-morbidities. covid-19 confirmed by molecular or antigenic test for sars-cov-2 within up to 24 hours prior to screening and a maximum of 2 days after sample collection. viral syndrome with or without pneumonia and arterial o2 saturation > 94%. signing the free and informed consent form before any research procedures. willingness to use the proposed investigational treatment and follow the procedures provided for in the research.

a - inclusion criteria (except fluoxetine + budesonide and paracetamol arms): patients over 18 years old with the ability to provide free and informed consent acute flu-like symptoms < 07 days. patients with at least one enhancement criteria: age > 50 years. diabetes mellitus requiring oral medication or insulin. systemic arterial hypertension requiring at least 01 oral medication for bp control. known cardiovascular diseases (heart failure, congenital heart disease, valvar heart valve disease, coronary artery disease, cardiomyopathies). symptomatic lung disease (emphysema, chronic bronchitis). symptomatic asthma patients requiring chronic use of agents for control of symptoms. fever > 38 c at baseline. obesity, defined as bmi> 30 kg / m2 body weight. transplanted patients. patient with stage iv chronic kidney disease or on dialysis. immunosuppressed patients/ using corticosteroid therapy (equivalent to maximum 10 mg of prednisone per day) and/ or immunosuppressive therapy). patients with a history of cancer in the last 05 years or undergoing treatment of a current cancer. chronic renal disease kdigo iv or end-stage renal disease on chronic ambulatory renal replacement therapy. patients with important limitation of daily activities due to: dyspnea, chest pain myalgia (limited to 25% of all randomizations). patient with positive rapid test for sars-cov2 antigen performed on occasion of the screening or patient with a positive sars-cov2 diagnostic test within 07 days of the onset of symptoms. willingness to use the proposed investigative treatment and follow the protocol-related procedures foreseen in the research. specific inclusion criteria for the fluvoxamine arm: present significant dyspnea, arterial hypotension, severe dehydration or spo2 between 85 to 93% in room air at admission and medical decision to discharge patient home, with an observation period at er not exceeding 12 hours. b - inclusion criteria for the fluoxetine + budesonide combination arm (07 days of treatment - partnership with the "anticov consortium"): patients over 18 years of age with the ability to provide free and informed consent. patients treated at a basic health unit of the unified health system (sus) or patients treated at emergency care units of the sus or supplementary medicine with an acute clinical condition compatible with covid 19. patients over 18 years of age and a history of at least one of the following criteria. diabetes mellitus, heart disease, chronic kidney disease, chronic obstructive pulmonary disease, cerebrovascular diseases or patients considered to be underweight or overweight according to the investigator's judgment (bmi ≤ 16 or bmi > 25). or individuals aged ≥ 60 years without co-morbidities. covid-19 confirmed by molecular or antigenic test for sars-cov-2 within up to 24 hours prior to screening and a maximum of 2 days after sample collection. viral syndrome with or without pneumonia and arterial o2 saturation > 94%. signing the free and informed consent form before any research procedures. willingness to use the proposed investigational treatment and follow the procedures provided for in the research.

inclusion criteria: patients over 18 years old with the ability to provide free and informed consent acute flu-like symptoms < 07 days. patients with at least one enhancement criteria: age > 50 years; diabetes mellitus requiring oral medication or insulin systemic arterial hypertension requiring at least 01 oral medication for bp control; known cardiovascular diseases (heart failure, congenital heart disease, valvar heart valve disease, coronary artery disease, cardiomyopathies) symptomatic lung disease (emphysema, chronic bronchitis) symptomatic asthma patients requiring chronic use of agents for control of symptoms. fever > 38 c at baseline obesity, defined as bmi> 30 kg / m2 body weight transplanted patients patient with stage iv chronic kidney disease or on dialysis. immunosuppressed patients/ using corticosteroid therapy (equivalent to maximum 10 mg of prednisone per day) and/ or immunosuppressive therapy) patients with a history of cancer in the last 05 years or undergoing treatment of a current cancer chronic renal disease kdigo iv or end-stage renal disease on chronic ambulatory renal replacement therapy patients with important limitation of daily activities due to: dyspnea, chest pain myalgia (limited to 25% of all randomizations) patient with positive rapid test for sars-cov2 antigen performed on occasion of the screening or patient with a positive sars-cov2 diagnostic test within 07 days of the onset of symptoms. willingness to use the proposed investigative treatment and follow the protocol-related procedures foreseen in the research specific inclusion criteria for the fluvoxamine arm: present significant dyspnea, arterial hypotension, severe dehydration or spo2 between 85 to 93% in room air at admission and medical decision to discharge patient home, with an observation period at er not exceeding 12 hours.

inclusion criteria: patients over 18 years old with the ability to provide free and informed consent acute flu-like symptoms < 07 days. patients with at least one enhancement criteria: age > 50 years; diabetes mellitus requiring oral medication or insulin systemic arterial hypertension requiring at least 01 oral medication for bp control; known cardiovascular diseases (heart failure, congenital heart disease, valvar heart valve disease, coronary artery disease, cardiomyopathies) symptomatic lung disease (emphysema, chronic bronchitis) symptomatic asthma patients requiring chronic use of agents for control of symptoms. fever > 38 c at baseline obesity, defined as bmi> 30 kg / m2 body weight transplanted patients patient with stage iv chronic kidney disease or on dialysis. immunosuppressed patients/ using corticosteroid therapy (equivalent to maximum 10 mg of prednisone per day) and/ or immunosuppressive therapy) patients with a history of cancer in the last 05 years or undergoing treatment of a current cancer chronic renal disease kdigo iv or end-stage renal disease on chronic ambulatory renal replacement therapy patients with important limitation of daily activities due to: dyspnea, chest pain myalgia (limited to 25% of all randomizations) patient with positive rapid test for sars-cov2 antigen performed on occasion of the screening or patient with a positive sars-cov2 diagnostic test within 07 days of the onset of symptoms. willingness to use the proposed investigative treatment and follow the protocol-related procedures foreseen in the research specific inclusion criteria for the fluvoxamine arm: present significant dyspnea, arterial hypotension, severe dehydration or spo2 between 85 to 93% in room air at admission and medical decision to discharge patient home, with an observation period at er not exceeding 12 hours.

inclusion criteria: patients over 18 years old with the ability to provide free and informed consent acute flu-like symptoms < 07 days. patients with at least one enhancement criteria: age > 50 years; diabetes mellitus requiring oral medication or insulin systemic arterial hypertension requiring at least 01 oral medication for bp control; known cardiovascular diseases (heart failure, congenital heart disease, valvar heart valve disease, coronary artery disease, cardiomyopathies) symptomatic lung disease (emphysema, chronic bronchitis) symptomatic asthma patients requiring chronic use of agents for control of symptoms. fever > 38 c at baseline obesity, defined as bmi> 30 kg / m2 body weight transplanted patients patient with stage iv chronic kidney disease or on dialysis. immunosuppressed patients/ using corticosteroid therapy (equivalent to maximum 10 mg of prednisone per day) and/ or immunosuppressive therapy) patients with a history of cancer in the last 05 years or undergoing treatment of a current cancer chronic renal disease kdigo iv or end-stage renal disease on chronic ambulatory renal replacement therapy patients with important limitation of daily activities due to: dyspnea, chest pain myalgia (limited to 25% of all randomizations) patient with positive rapid test for sars-cov2 antigen performed on occasion of the screening or patient with a positive sars-cov2 diagnostic test within 07 days of the onset of symptoms. willingness to use the proposed investigative treatment and follow the protocol-related procedures foreseen in the research

inclusion criteria: patients over 18 years old with the ability to provide free and informed consent acute flu-like symptoms < 07 days. patients with at least one enhancement criteria: age > 50 years; diabetes mellitus requiring oral medication or insulin systemic arterial hypertension requiring at least 01 oral medication for bp control; known cardiovascular diseases (heart failure, congenital heart disease, valvar heart valve disease, coronary artery disease, cardiomyopathies) symptomatic lung disease (emphysema, chronic bronchitis) symptomatic asthma patients requiring chronic use of agents for control of symptoms. fever > 38 c at baseline obesity, defined as bmi> 30 kg / m2 body weight transplanted patients patient with stage iv chronic kidney disease or on dialysis. immunosuppressed patients/ using corticosteroid therapy (equivalent to maximum 10 mg of prednisone per day) and/ or immunosuppressive therapy) patients with a history of cancer in the last 05 years or undergoing treatment of a current cancer chronic renal disease kdigo iv or end-stage renal disease on chronic ambulatory renal replacement therapy patients with important limitation of daily activities due to: dyspnea, chest pain myalgia (limited to 25% of all randomizations) patient with positive rapid test for sars-cov2 antigen performed on occasion of the screening or patient with a positive sars-cov2 diagnostic test within 07 days of the onset of symptoms. willingness to use the proposed investigative treatment and follow the protocol-related procedures foreseen in the research

inclusion criteria: 1. patients over 18 years old with the ability to provide free and informed consent 2. acute flu-like symptoms < 07 days. 3. patients with at least one enhancement criteria: 1. age > 50 years; 2. diabetes mellitus requiring oral medication or insulin 3. systemic arterial hypertension requiring at least 01 oral medication for bp control; 4. known cardiovascular diseases (heart failure, congenital heart disease, valvar heart valve disease, coronary artery disease, cardiomyopathies) 5. symptomatic lung disease (emphysema, chronic bronchitis) 6. symptomatic asthma patients requiring chronic use of agents for control of symptoms. 7. fever > 38 c at baseline 8. obesity, defined as bmi> 30 kg / m2 body weight 9. transplanted patients 10. patient with stage iv chronic kidney disease or on dialysis. 11. immunosuppressed patients/ using corticosteroid therapy (equivalent to maximum 10 mg of prednisone per day) and/ or immunosuppressive therapy) 12. patients with a history of cancer in the last 05 years or undergoing treatment of a current cancer 13. chronic renal disease kdigo iv or end-stage renal disease on chronic ambulatory renal replacement therapy 14. patients with important limitation of daily activities due to: dyspnea, chest pain myalgia (limited to 25% of all randomizations) 4. patient with positive rapid test for sars-cov2 antigen performed on occasion of the screening or patient with a positive sars-cov2 diagnostic test within 07 days of the onset of symptoms. 5. willingness to use the proposed investigative treatment and follow the protocol-related procedures foreseen in the research

inclusion criteria: 1. patients over 18 years old with the ability to provide free and informed consent 2. acute flu-like symptoms < 07 days. 3. patients with at least one enhancement criteria: 1. age > 50 years; 2. diabetes mellitus requiring oral medication or insulin 3. systemic arterial hypertension requiring at least 01 oral medication for bp control; 4. known cardiovascular diseases (heart failure, congenital heart disease, valvar heart valve disease, coronary artery disease, cardiomyopathies) 5. symptomatic lung disease (emphysema, chronic bronchitis) 6. symptomatic asthma patients requiring chronic use of agents for control of symptoms. 7. fever > 38 c at baseline 8. obesity, defined as bmi> 30 kg / m2 body weight 9. transplanted patients 10. patient with stage iv chronic kidney disease or on dialysis. 11. immunosuppressed patients/ using corticosteroid therapy (equivalent to maximum 10 mg of prednisone per day) and/ or immunosuppressive therapy) 12. patients with a history of cancer in the last 05 years or undergoing treatment of a current cancer 13. chronic renal disease kdigo iv or end-stage renal disease on chronic ambulatory renal replacement therapy 14. patients with important limitation of daily activities due to: dyspnea, chest pain myalgia (limited to 25% of all randomizations) 4. patient with positive rapid test for sars-cov2 antigen performed on occasion of the screening or patient with a positive sars-cov2 diagnostic test within 07 days of the onset of symptoms. 5. willingness to use the proposed investigative treatment and follow the protocol-related procedures foreseen in the research

inclusion criteria: 1. patients over 18 years old with the ability to provide free and informed consent 2. acute flu-like symptoms < 07 days. 3. all patient need to have at lease one enhancement factor: 1. age > 50 years; 2. diabetes mellitus requiring oral medication or insulin 3. systemic arterial hypertension requiring at least 01 oral medication for bp control; 4. known cardiovascular diseases (heart failure, congenital heart disease, valvar heart valve disease, coronary artery disease, cardiomyopathies) 5. symptomatic lung disease (emphysema, chronic bronchitis) 6. symptomatic asthma patients requiring chronic use of agents for control of symptoms. 7. smoking 8. obesity, defined as bmi> 30 kg / m2 body weight 9. transplanted patients 10. patient with stage iv chronic kidney disease or on dialysis. 11. immunosuppressed patients / using corticosteroid therapy (equivalent to at least 10 mg of prednisone per day) and / or immunosuppressive therapy) 12. patients with a history of cancer in the last 05 years or undergoing treatment of a current cancer 13. chronic renal disease kdigo iv or end-stage renal disease on chronic ambulatory renal replacement therapy 4. patient with positive rapid test for sars-cov2 antigen performed on occasion of the screening or patient with a positive sars-cov2 diagnostic test within 07 days of the onset of symptoms. 5. willingness to use the proposed investigative treatment and follow the protocol-related procedures foreseen in the research

inclusion criteria: 1. patients over 18 years old with the ability to provide free and informed consent 2. acute flu-like symptoms < 07 days. 3. all patient need to have at lease one enhancement factor: 1. age > 50 years; 2. diabetes mellitus requiring oral medication or insulin 3. systemic arterial hypertension requiring at least 01 oral medication for bp control; 4. known cardiovascular diseases (heart failure, congenital heart disease, valvar heart valve disease, coronary artery disease, cardiomyopathies) 5. symptomatic lung disease (emphysema, chronic bronchitis) 6. symptomatic asthma patients requiring chronic use of agents for control of symptoms. 7. smoking 8. obesity, defined as bmi> 30 kg / m2 body weight 9. transplanted patients 10. patient with stage iv chronic kidney disease or on dialysis. 11. immunosuppressed patients / using corticosteroid therapy (equivalent to at least 10 mg of prednisone per day) and / or immunosuppressive therapy) 12. patients with a history of cancer in the last 05 years or undergoing treatment of a current cancer 13. chronic renal disease kdigo iv or end-stage renal disease on chronic ambulatory renal replacement therapy 4. patient with positive rapid test for sars-cov2 antigen performed on occasion of the screening or patient with a positive sars-cov2 diagnostic test within 07 days of the onset of symptoms. 5. willingness to use the proposed investigative treatment and follow the protocol-related procedures foreseen in the research

inclusion criteria: 1. patients over 18 years old with the ability to provide free and informed consent 2. acute flu-like symptoms < 07 days. 3. all patient need to have at lease one enhancement factor: 1. age > 50 years; 2. diabetes mellitus requiring oral medication or insulin 3. systemic arterial hypertension requiring at least 01 oral medication for bp control; 4. known cardiovascular diseases (heart failure, congenital heart disease, valvar heart valve disease, coronary artery disease, cardiomyopathies) 5. symptomatic lung disease (emphysema, chronic bronchitis) 6. symptomatic asthma patients requiring chronic use of agents for control of symptoms. 7. smoking 8. obesity, defined as bmi> 30 kg / m2 body weight 9. transplanted patients 10. sars-cov2 vaccinated patients 11. patient with stage iv chronic kidney disease or on dialysis. 12. immunosuppressed patients / using corticosteroid therapy (equivalent to at least 10 mg of prednisone per day) and / or immunosuppressive therapy) 13. patients with a history of cancer in the last 05 years or undergoing treatment of a current cancer 4. patient with positive rapid test for sars-cov2 antigen performed on occasion of the screening or patient with a positive sars-cov2 diagnostic test within 07 days of the onset of symptoms. 5. willingness to use the proposed investigative treatment and follow the protocol-related procedures foreseen in the research

inclusion criteria: 1. patients over 18 years old with the ability to provide free and informed consent 2. acute flu-like symptoms < 07 days. 3. all patient need to have at lease one enhancement factor: 1. age > 50 years; 2. diabetes mellitus requiring oral medication or insulin 3. systemic arterial hypertension requiring at least 01 oral medication for bp control; 4. known cardiovascular diseases (heart failure, congenital heart disease, valvar heart valve disease, coronary artery disease, cardiomyopathies) 5. symptomatic lung disease (emphysema, chronic bronchitis) 6. symptomatic asthma patients requiring chronic use of agents for control of symptoms. 7. smoking 8. obesity, defined as bmi> 30 kg / m2 body weight 9. transplanted patients 10. sars-cov2 vaccinated patients 11. patient with stage iv chronic kidney disease or on dialysis. 12. immunosuppressed patients / using corticosteroid therapy (equivalent to at least 10 mg of prednisone per day) and / or immunosuppressive therapy) 13. patients with a history of cancer in the last 05 years or undergoing treatment of a current cancer 4. patient with positive rapid test for sars-cov2 antigen performed on occasion of the screening or patient with a positive sars-cov2 diagnostic test within 07 days of the onset of symptoms. 5. willingness to use the proposed investigative treatment and follow the protocol-related procedures foreseen in the research